Beyond Meat vs Medifast
BYND and MED side by side, both in food and kindred products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BYND and MED compare
Medifast is the larger company, worth 1.5 times as much as Beyond Meat ($145M against $98.5M).
Beyond Meat grew revenue faster over the last twelve months (−12.9% versus −30.3% for Medifast).
Beyond Meat keeps more of each dollar of sales as profit, with a net margin of 124% compared with −13.6% at Medifast.
Medifast scores higher on the StockData Score (10 against 5 for Beyond Meat), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BYND | MED |
|---|---|---|
| Size and price | ||
| Market cap | $98.5M | $145M |
| Share price | $5.38 | $12.97 |
| Change, 1 year | −83.9% | 11.5% |
| Change, 5 years | −99.8% | −94.1% |
| Beta (5Y) | 2.00 | 0.71 |
| Employees | 589 | 380 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 0.5× |
| P/B | – | 0.8× |
| FCF yield | −90.9% | −2.7% (better) |
| Fair value | – | $35.80 |
| Margin of safety | – | 63.8% |
| Growth | ||
| Revenue growth (TTM) | −12.9% (better) | −30.3% |
| Revenue growth, 5Y average | −7.5% (better) | −16.2% |
| Net income growth (TTM) | – | −16573% |
| EPS growth (TTM) | – | −37000% |
| Profitability | ||
| Gross margin | 8.6% | 69.2% (better) |
| Operating margin | −118% | −11.6% (better) |
| Net margin | 124% (better) | −13.6% |
| FCF margin | −35.4% | −1.3% (better) |
| Return on equity | – | −20.7% |
| Return on invested capital | −125% | −110% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −11.1× | – |
| Current ratio | 3.12 | 4.82 (better) |
| Altman Z-score | −4.64 | 3.83 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 21.9% | 73.9% |
| Held by insiders | – | 12.3% |
| Insider net buying, 12 months | −$282K | $1.5M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 13.2% |
Go deeper
- BYND stock overview
- BYND income statement
- BYND valuation and score
- MED stock overview
- MED income statement
- MED valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.